Prognostication in patients with idiopathic pulmonary fibrosis using quantitative airway analysis from HRCT: a retrospective study.

Journal: The European respiratory journal
Published Date: Jul 31, 2025

Abstract

BACKGROUND: Predicting shorter life expectancy is crucial for prioritizing antifibrotic therapy in fibrotic lung diseases, where progression varies widely, from stability to rapid deterioration. This heterogeneity complicates treatment decisions, emphasizing the need for reliable baseline measures. This study focuses on leveraging artificial intelligence model to address heterogeneity in disease outcomes, focusing on mortality as the ultimate measure of disease trajectory.

Authors

  • Yang Nan
  • Felder N Federico
    Royal Brompton Hospital, London, UK.
  • Stephen Humphries
    Institute of Cardiovascular Science, University College London, London, UK.
  • John A Mackintosh
    Queensland Lung Transplant Service, The Prince Charles Hospital, Brisbane, Queensland, Australia.
  • Christopher Grainge
    Department of Respiratory Medicine, New Lambton Heights, John Hunter Hospital, New South Wales, Australia.
  • Helen E Jo
    Respiratory Medicine, Royal Prince Alfred Hospital, New South Wales, Australia.
  • Nicole Goh
    Yale-NUS College, Singapore, Singapore.
  • Paul N Reynolds
    Lung Research, Hanson Institute, Adelaide, South Australia, Australia.
  • Peter M A Hopkins
    Queensland Lung Transplant Service, The Prince Charles Hospital, Brisbane, Queensland, Australia.
  • Vidya Navaratnam
    Sir Charles Gairdner Hospital, The University of Western Australia, Australia.
  • Yuben Moodley
    School of Medicine & Pharmacology, University of Western Australia, Perth, Western Australia, Australia.
  • Haydn Walters
    Allergy and Lung Health Unit, School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia.
  • Samantha Ellis
    Department of Radiology, Alfred Health, Melbourne, Victoria, Australia; and.
  • Gregory Keir
    Department of Respiratory Medicine, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
  • Chris Zappala
    Hervey Bay Hospital, Queensland & University of Queensland.
  • Tamera Corte
    Royal Prince Alfred Hospital, The University of Sydney, Camperdown, Australia.
  • Ian Glaspole
    Department of Allergy and Respiratory Medicine, Alfred Hospital, Melbourne, Victoria, Australia.
  • Athol U Wells
    Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK.
  • Guang Yang
    National Heart and Lung Institute, Imperial College London, London, UK.
  • Simon Lf Walsh
    National Heart and Lung Institute, Imperial College London, London SW3 6LY, UK. Electronic address: s.walsh@imperial.ac.uk.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals